睿知中国医院研究地图
候选清单

广州中山大学

中山大学附属第三医院

Third Affiliated Hospital of Sun Yat-sen University

在本站收录的 53 种疾病中,这家医院列在其中 26 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

中山大学附属第三医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma10 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma171 篇牵头论文牵头 3 项开放试验
  3. 胃癌Stomach cancer15 篇牵头论文
  4. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  5. 骨肉瘤Osteosarcoma2 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma4 篇牵头论文
  9. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis1 篇牵头论文
  10. β 地中海贫血Beta thalassaemia0 篇牵头论文
  11. 范可尼贫血Fanconi anaemia1 篇牵头论文
  12. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder39 篇牵头论文牵头 2 项开放试验
  13. 重症肌无力Myasthenia gravis0 篇牵头论文牵头 1 项开放试验
  14. 烟雾病Moyamoya disease3 篇牵头论文
  15. 肝豆状核变性Wilson disease0 篇牵头论文
  16. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis22 篇牵头论文
  17. 大动脉炎Takayasu arteritis2 篇牵头论文
  18. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  19. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
  20. 白塞病Behçet disease0 篇牵头论文
  21. Alport 综合征Alport syndrome1 篇牵头论文
  22. IgA 肾病IgA nephropathy0 篇牵头论文
  23. 尼曼-匹克病 C 型Niemann–Pick disease type C0 篇牵头论文
  24. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
  25. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  26. 遗传性血管性水肿Hereditary angioedema0 篇牵头论文

未列出的收录疾病:食管鳞状细胞癌、视网膜母细胞瘤、脊索瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、IgG4相关性疾病、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、戈谢病、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.4%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 1120232024: 2220242025: 332025

广州有 24 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术副作用与生活质量复发与转移
论文中的科室放疗科影像/核医学科耳鼻喉/头颈外科
牵头的论文10
  1. EBNA1 Targeted Ultra-Small Near-Infrared Persistent Luminescent Nano-Inhibitor for Theranostics of EBV-Associated Cancer.2025Advanced healthcare materials
  2. Video tracking-based mandibular movement kinematic analysis in patients with nasopharyngeal carcinoma.2025European journal of medical research免费全文
  3. Effects of minimum monitor unit per dynamic control point on intensity-modulated radiotherapy planning for nasopharyngeal carcinoma: A retrospective study.2025Medical dosimetry : official journal of the American Association of Medical Dosimetrists
  4. Characteristics of Tongue Pressure Measured by Novel Multisite Flexible Sensors in Nasopharyngeal Carcinoma Patients With Dysphagia.2024Archives of physical medicine and rehabilitation
  5. Increased CCT5 expression is a potential unfavourable factor promoting the growth of nasopharyngeal carcinoma.2024The Journal of international medical research免费全文
  6. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?2023Cancer medicine免费全文
  7. Effect of Intensive Oropharyngeal Training on Radiotherapy-Related Dysphagia in Nasopharyngeal Carcinoma Patients.2022Dysphagia
  8. Influence of beamlet width on dynamic IMRT plan quality in nasopharyngeal carcinoma.2022PeerJ免费全文
  9. Prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma: A retrospective study.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  10. Influence of tumor necrosis on treatment sensitivity and long-term survival in nasopharyngeal carcinoma.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
中文论文(未计入)2
  1. [The objective and material selection of skull base reconstruction after radiotherapy for nasopharyngeal carcinoma].2025Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [miR-18a enhances the radiosensitivity of nasopharyngeal carcinoma cells through inducing autophagy].2021Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
PubMed 以外找到的论文(未计入)6
  1. Novel genetic algorithm‐based individual treatment effect scoring model for optimizing decision‐making: Induction chemotherapy in nasopharyngeal carcinoma2025Open Research (University of Surrey)论文
  2. Prognostic Value of Parapharyngeal Involvement Subclassifications Divided by Parapharyngeal Muscles in Nasopharyngeal Carcinoma: A Study of 1752 Patients from Two Centers2024Research Square预印本
  3. The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial.2024Journal of Clinical Oncology会议摘要
  4. Synthetic computed tomography generation from multi-sequence magnetic resonance images for nasopharyngeal carcinoma treatment planning via cycle-consistent generative adversarial network2023Research Square预印本
  5. Effect of Exercise on Sternoceleidomastoid Muscular Fibrosis after Radiotherapy for Nasopharyngeal Carcinoma Patients Analyzed by Shear-Wave Elastography2022Rehabilitation Medicine论文
  6. Effect of the number of control points on the plan quality of intensity-modulated radiotherapy for nasopharyngeal carcinoma2021Journal of Radiation Research and Applied Sciences论文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 171 篇,占 1.2%。

牵头论文
171
2021–2025 年
牵头试验
11
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 383820212022: 292920222023: 363620232024: 222220242025: 41412025

广州有 15 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
    分期
    不分期
    开始
    2023-08
    登记号
    NCT05984511

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学附属第三医院广州

  2. 正在招募
    Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
    分期
    不分期
    开始
    2022-08
    登记号
    NCT05484908

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学附属第三医院广州

  3. 即将招募
    Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
    分期
    II期
    开始
    2025-03
    登记号
    NCT06900478

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:中山大学附属第三医院广州

  4. 正在招募
    A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07589244

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州

  5. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、大连、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  6. 正在招募
    Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
    分期
    未注明
    开始
    2023-05
    登记号
    NCT06746701

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中南大学湘雅医院;另有 2 家列出的医院为研究中心广州、衡阳、长沙

  7. 即将招募
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    分期
    III期
    开始
    2025-01
    登记号
    NCT06779461

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、兰州、南京、天津、广州、蚌埠、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室影像/核医学科普外/肝胆胰外科消化/肝病科肿瘤内科
牵头的论文171
  1. Diagnostic performance of dual-layer spectral detector CT derived from the arterial and portal venous phases in small HCC (≤ 30 mm): comparison with multiphase CT and MRI.2026Abdominal radiology (New York)
  2. Multi-faceted nanodrug reinforcing metalloimmunotherapy for hepatocellular carcinoma.2026Biomaterials
  3. Hyperbaric oxygen targets RCN1 to modulate ER-mitochondria crosstalk and ameliorate sorafenib resistance in hepatocellular carcinoma.2026Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  4. LI-RADS categories and clinicopathological features predict recurrence-free survival in patients with radical resected hepatocellular carcinoma.2026European journal of radiology
  5. Alcohol activates ATF4/LPLA2-mediated BMP metabolism to enhance HBV-induced hepatocellular carcinogenesis.2026Journal of hepatology
  6. RP11-439C15.4 inhibits the malignant progression of hepatocellular carcinoma via binding to DHX9 and facilitating its degradation.2025Acta biochimica et biophysica Sinica免费全文
  7. CircRNA-mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c-Myc Axis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  8. Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  9. Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease.2025Annals of hepatology
  10. Predicting the occurrence of liver injury induced by immune checkpoint inhibitors in hepatocellular carcinoma patients: a retrospective analysis.2025BMC cancer免费全文
  11. Dynamic changes in liver stiffness measurement by 2D shear-wave elastography predict hepatocellular carcinoma in patients with chronic hepatitis B and well-controlled viremia: a retrospective study.2025BMC gastroenterology免费全文
  12. A self-gelling hemostatic powder boosting radiotherapy-elicited NK cell immunity to combat postoperative hepatocellular carcinoma relapse.2025Biomaterials
  13. Lactate accumulation drives hepatocellular carcinoma metastasis through facilitating tumor-derived exosome biogenesis by Rab7A lactylation.2025Cancer letters
  14. NEIL3 Deficiency Enhances HCC Cell Sensitivity to Oxaliplatin by Inhibiting the Fanconi Anaemia Pathway.2025Cell biology international
  15. Nucleolar NOL9 regulated by DNA methylation promotes hepatocellular carcinoma growth through activation of Wnt/β-catenin signaling pathway.2025Cell death & disease免费全文
  16. Tissue-resident peripheral helper T cells foster hepatocellular carcinoma immune evasion by promoting regulatory B-cell expansion.2025Chinese medical journal免费全文
  17. Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma.2025Clinical cancer research : an official journal of the American Association for Cancer Research
  18. Post-treatment adverse events ranking in targeted immunotherapy for hepatocellular carcinoma: A network meta-analysis based on risk probability assessment.2025Critical reviews in oncology/hematology
  19. Exosome-derived lnc-FAM72D-3 promotes lenvatinib resistance by remodeling hepatocellular carcinoma cytoskeleton via MBNL1/FAK axis.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  20. MR elastography-based prediction of development of hepatocellular carcinoma in patients with chronic hepatitis B with sustained virological response.2025European radiology
  21. Three-dimensional MR elastography-based stiffness for assessing the status of Ki67 proliferation index and Cytokeratin-19 in hepatocellular carcinoma.2025European radiology
  22. METTL3 knockout accelerates hepatocarcinogenesis via inhibiting endoplasmic reticulum stress response.2025FEBS open bio免费全文
  23. Serglycin's role in primary liver cancer: insights into tumor microenvironment and macrophage interaction.2025Frontiers in immunology免费全文
  24. HDAC inhibitor MS275 reprograms metabolism to induce differentiation and suppress proliferation in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  25. Case Report: Split liver transplantation for graft liver failure due to antibody-mediated rejection after immune checkpoint inhibitor therapy.2025Frontiers in immunology免费全文
  26. Integrative spatial and single-cell transcriptomics elucidate programmed cell death-driven tumor microenvironment dynamics in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  27. Unraveling the potential mechanism and prognostic value of pentose phosphate pathway in hepatocellular carcinoma: a comprehensive analysis integrating bulk transcriptomics and single-cell sequencing data.2025Functional & integrative genomics
  28. CircPIK3C3 inhibits hepatocellular carcinoma progression and lenvatinib resistance by suppressing the Wnt/β-catenin pathway via the miR-452-5p/SOX15 axis.2025Genomics
  29. Clinical Features of HBV-Related HCC in Long-Term NAs-Treated Versus Untreated Patients.2025Journal of cellular and molecular medicine免费全文
  30. Prognostic Value of a Novel Model for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization.2025Journal of clinical laboratory analysis免费全文
  31. CRSP8-driven fatty acid metabolism reprogramming enhances hepatocellular carcinoma progression by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling.2025Journal of experimental & clinical cancer research : CR免费全文
  32. Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase.2025Journal of gastroenterology and hepatology
  33. Intertumoral Heterogeneity Based on MRI Radiomic Features Estimates Recurrence in Hepatocellular Carcinoma.2025Journal of magnetic resonance imaging : JMRI
  34. A facile combined therapy of chemotherapeutic agent and microRNA for hepatocellular carcinoma using non-cationic nanogel.2025Journal of materials chemistry. B
  35. Drug-loaded indocyanine green J-aggregates activate metalloimmunotherapy for sustained photothermal therapy of hepatocellular carcinoma.2025Journal of nanobiotechnology免费全文
  36. Radiotherapy plus a self-gelation powder encapsulating tRF5-GlyGCC inhibitor potentiates natural kill cell immunity to prevent hepatocellular carcinoma recurrence.2025Journal of nanobiotechnology免费全文
  37. EMP1 + hepatic stellate cells drive hepatic fibrosis progression to hepatocellular carcinoma and predict prognosis.2025Journal of translational medicine免费全文
  38. The hybrid lipoplex induces cytoskeletal rearrangement via autophagy/RhoA signaling pathway for enhanced anticancer gene therapy.2025Nature communications免费全文
  39. Semiquantitative analysis of 18F-aluminum fluoride fibroblast activation protein inhibitor 42 PET/computed tomography in primary liver cancer and factors influencing imaging positivity rates.2025Nuclear medicine communications
  40. Oncolytic virus therapy in hepatocellular carcinoma.2025Oncology research免费全文
  41. Interactive Explainable Deep Learning Model for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI: A Retrospective, Multicenter, Diagnostic Study.2025Radiology. Imaging cancer免费全文
  42. Machine learning-assisted multi-dimensional transcriptomic analysis of cytoskeleton-related molecules and their relationship with prognosis in hepatocellular carcinoma.2025Scientific reports免费全文
  43. Late course adaptive radiotherapy based on tumor volume reduction decreases Gastrointestinal toxicity for abdominal lymph node metastasis of hepatocellular carcinoma.2025Scientific reports免费全文
  44. Development and clinical validation of a novel platelet count-based nomogram for predicting microvascular invasion in HCC.2025Scientific reports免费全文
  45. Comparative analysis of hepatectomy for HCC with PVTT: Insights from a 30-year single-center experience: Hepatectomy for HCC with PVTT.2025Surgical oncology
  46. Predicting early recurrence of hepatocellular carcinoma after thermal ablation based on longitudinal MRI with a deep learning approach.2025The oncologist免费全文
  47. Anatomical thermal ablation as an alternative to surgical resection for subcapsular hepatocellular carcinoma.2024Abdominal radiology (New York)
  48. Mean ADC values and arterial phase hyperintensity discriminate small (≤ 3 cm) well-differentiated hepatocellular carcinoma from dysplastic nodule.2024Abdominal radiology (New York)
  49. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.2024Academic radiology
  50. Clinicopathologic features and tumor immune microenvironment of lymphocyte-rich hepatocellular carcinoma.2024Annals of diagnostic pathology
  51. Clinical outcomes of modified transarterial chemoembolization vs. drug-eluting bead transarterial chemoembolization as initial treatment for single hepatocellular carcinoma: a propensity score matching analysis.2024Annals of medicine免费全文
  52. A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  53. Dynamic network biomarker C1QTNF1 regulates tumor formation at the tipping point of hepatocellular carcinoma.2024Biomolecules & biomedicine免费全文
  54. Evaluation of the effectiveness of surgical resection and ablation for the treatment of early-stage hepatocellular carcinoma: A retrospective cohort study.2024Cancer reports (Hoboken, N.J.)免费全文
  55. COLEC10 inhibits the stemness of hepatocellular carcinoma by suppressing the activity of β-catenin signaling.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  56. Evaluating the impact of treatment sequencing on outcomes in hepatocellular carcinoma: a comparative analysis of TACE and systemic therapies.2024Clinical and experimental medicine免费全文
  57. A Novel Oncogenic Role of Disulfidptosis-related Gene SLC7A11 in Anti-tumor Immunotherapy Response to Human Cancers.2024Current cancer drug targets
  58. Insights into the accumulation and hepatobiliary transport of bisphenols (BPs) in liver and bile.2024Environmental research
  59. New strategy of LI-RADS v2018 to improve the sensitivity for small hepatocellular carcinoma ≤ 3.0 cm on extracellular-contrast enhanced MRI.2024European journal of radiology
  60. Assessment of arterial-phase hyperenhancement and late-phase washout of hepatocellular carcinoma-a meta-analysis of contrast-enhanced ultrasound (CEUS) with SonoVue® and Sonazoid®.2024European radiology
  61. Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.2024Hepatology (Baltimore, Md.)
  62. APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways.2024International immunopharmacology
  63. Interleukin-25 as a Potential Biomarker in Lung Metastasis of Hepatocellular Carcinoma with HBV History in Chinese Patients: A Single Center, Case-control Study.2024International journal of medical sciences免费全文
  64. Distribution of per- and polyfluoroalkyl substances in blood, serum, and urine of patients with liver cancer and associations with liver function biomarkers.2024Journal of environmental sciences (China)
  65. Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study.2024Medicine免费全文
  66. CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p/NUPR1/FTH1 axis.2024Molecular cancer免费全文
  67. Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study.2024Scientific reports免费全文
  68. Microinvasion in hepatocellular carcinoma: predictive factor and application for definition of clinical target volume for radiotherapy.2024World journal of surgical oncology免费全文
  69. 18F-FDG PET/CT-based radiomics nomogram for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma: a two-center study.2023Abdominal radiology (New York)
  70. The Conserved LncRNA DIO3OS Restricts Hepatocellular Carcinoma Stemness by Interfering with NONO-Mediated Nuclear Export of ZEB1 mRNA.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  71. Hepatitis B virus X protein induces p16 gene promoter methylation through upregulation of DNA methylation transferases DNMT1 and DNMT3A.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  72. Letter: Causal relationship between aspirin and the risk of hepatocellular carcinoma remains unproven.2023Alimentary pharmacology & therapeutics
  73. Transcriptional analysis of the expression and prognostic value of lipid droplet-localized proteins in hepatocellular carcinoma.2023BMC cancer免费全文
  74. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.2023Biomaterials
  75. Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.2023Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  76. PTTG1 Reprograms Asparagine Metabolism to Promote Hepatocellular Carcinoma Progression.2023Cancer research
  77. Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence.2023Current oncology (Toronto, Ont.)免费全文
  78. Splicing factor SNRPA associated with microvascular invasion promotes hepatocellular carcinoma metastasis through activating NOTCH1/Snail pathway and is mediated by circSEC62/miR-625-5p axis.2023Environmental toxicology
  79. Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma.2023Epigenetics免费全文
  80. The value of quantitative MR elastography-based stiffness for assessing the microvascular invasion grade in hepatocellular carcinoma.2023European radiology
  81. SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.2023Free radical biology & medicine
  82. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.2023Frontiers in immunology免费全文
  83. Preoperative prediction model of microvascular invasion in patients with hepatocellular carcinoma.2023HPB : the official journal of the International Hepato Pancreato Biliary Association
  84. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from2023Hepatology international
  85. Lnc-ZEB2-19 Inhibits the Progression and Lenvatinib Resistance of Hepatocellular Carcinoma by Attenuating the NF-κB Signaling Pathway through the TRA2A/RSPH14 Axis.2023International journal of biological sciences免费全文
  86. Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.2023Investigational new drugs
  87. Response to 'Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC' by Yang et al.2023Journal for immunotherapy of cancer免费全文
  88. Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma.2023Journal of experimental & clinical cancer research : CR免费全文
  89. RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization.2023Journal of experimental & clinical cancer research : CR免费全文
  90. CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect.2023Journal of experimental & clinical cancer research : CR免费全文
  91. Combined inhibition of surface CD51 and γ-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma.2023Journal of hepatology
  92. Expression and prognostic value of DNA sensors in hepatocellular carcinoma.2023Journal of leukocyte biology
  93. Efficacy of Multiple Modified Methods of Criteria for LR-M Liver Nodules of Different Sizes: Clinical Practice and Discussion in CEUS LI-RADS Version 2017.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  94. Long-term Outcomes of Patients with Hepatocellular Carcinoma Who Underwent Microwave Ablation after Downstaging with Transarterial Chemoembolization to Barcelona Clinic Liver Cancer Stage A.2023Journal of vascular and interventional radiology : JVIR
  95. Preoperative Transarterial Chemoembolization of Hepatic Inflammatory Pseudotumor-Like Follicular Dendritic Cell Sarcoma to Downstage to Resection.2023Journal of vascular and interventional radiology : JVIR
  96. COLEC10 Induces Endoplasmic Reticulum Stress by Occupying GRP78 and Inhibits Hepatocellular Carcinoma.2023Laboratory investigation; a journal of technical methods and pathology
  97. PTTG1 alleviates acute alcoholic liver injury by inhibiting endoplasmic reticulum stress-induced hepatocyte pyroptosis.2023Liver international : official journal of the International Association for the Study of the Liver
  98. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells.2023Nature communications免费全文
  99. Dual-Energy CT Deep Learning Radiomics to Predict Macrotrabecular-Massive Hepatocellular Carcinoma.2023Radiology
  100. A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT.2023Radiology免费全文
  101. TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm).2023Technology in cancer research & treatment免费全文
  102. Erythroid-transdifferentiated myeloid cells promote portal vein tumor thrombus in hepatocellular carcinoma.2023Theranostics免费全文
  103. Development of a Risk Classifier to Predict Tumor Recurrence and Lenvatinib Benefits in Hepatocellular Carcinoma After Liver Transplantation.2023Transplantation proceedings
  104. Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy.2023World journal of gastroenterology免费全文
  105. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.2022AJR. American journal of roentgenologyRCT
  106. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?2022Abdominal radiology (New York)
  107. Prevention of major biliary complications by fusion imaging for thermal ablation of malignant liver tumors adjacent to the bile ducts: a preliminary comparative study.2022Abdominal radiology (New York)
  108. The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis.2022Abdominal radiology (New York)
  109. Association of phenotypic transformation of circulating tumor cells and early recurrence in patients with hepatocellular carcinoma following liver transplantation.2022Asian journal of surgery
  110. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.2022BMC cancer免费全文
  111. Effect of alcohol on clinical complications of hepatitis virus-induced liver cirrhosis: a consecutive ten-year study.2022BMC gastroenterology免费全文
  112. Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma.2022BMC surgery免费全文
  113. Sorafenib suppresses the activation of type I interferon pathway induced by RLR-MAVS and cGAS-STING signaling.2022Biochemical and biophysical research communications
  114. Injectable adhesive hemostatic gel with tumor acidity neutralizer and neutrophil extracellular traps lyase for enhancing adoptive NK cell therapy prevents post-resection recurrence of hepatocellular carcinoma.2022Biomaterials
  115. TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience.2022Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  116. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.2022Cancer immunology, immunotherapy : CII免费全文
  117. High Expression of POGK Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma.2022Current oncology (Toronto, Ont.)免费全文
  118. MR elastography as a biomarker for prediction of early and late recurrence in HBV-related hepatocellular carcinoma patients before hepatectomy.2022European journal of radiology免费全文
  119. MR Elastography-Based Shear Strain Mapping for Assessment of Microvascular Invasion in Hepatocellular Carcinoma.2022European radiology免费全文
  120. Deep Learning-Based Classification of Hepatocellular Nodular Lesions on Whole-Slide Histopathologic Images.2022Gastroenterology
  121. PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma.2022Genes免费全文
  122. DNA N6-methyladenine involvement and regulation of hepatocellular carcinoma development.2022Genomics
  123. A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes.2022Hepatology international
  124. Identification and Validation of a Prognostic Model Based on Three MVI-Related Genes in Hepatocellular Carcinoma.2022International journal of biological sciences免费全文
  125. Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.2022International journal of cancer
  126. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.2022Journal for immunotherapy of cancer免费全文
  127. Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-κBp65/HK2 signalling.2022Journal of experimental & clinical cancer research : CR免费全文
  128. The Immune Landscape of Hepatitis B Virus-Related Acute Liver Failure by Integration Analysis.2022Journal of immunology research免费全文
  129. Black phosphorus-Au-thiosugar nanosheets mediated photothermal induced anti-tumor effect enhancement by promoting infiltration of NK cells in hepatocellular carcinoma.2022Journal of nanobiotechnology免费全文
  130. Laminaria japonica Peptides Suppress Liver Cancer by Inducing Apoptosis: Possible Signaling Pathways and Mechanism.2022Marine drugs免费全文
  131. CAF-derived exosomes transmitted Gremlin-1 promotes cancer progression and decreases the sensitivity of hepatoma cells to sorafenib.2022Molecular carcinogenesis
  132. Identification of circRNAs involved in the development of hepatocellular carcinoma after insufficient radiofrequency ablation.2022Neoplasma
  133. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.2022World journal of gastroenterology免费全文
  134. Diagnostic accuracy of 3D magnetic resonance elastography for assessing histologic grade of hepatocellular carcinoma: comparison of three methods for positioning region of interest.2021Abdominal radiology (New York)免费全文
  135. Feasibility of 3D US/CEUS-US/CEUS fusion imaging-based ablation planning in liver tumors: a retrospective study.2021Abdominal radiology (New York)
  136. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.2021Abdominal radiology (New York)
  137. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  138. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma.2021Aging免费全文
  139. Identification of miRNAs as diagnostic and prognostic markers in hepatocellular carcinoma.2021Aging免费全文
  140. Value of KPNA4 as a diagnostic and prognostic biomarker for hepatocellular carcinoma.2021Aging免费全文
  141. HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G1/S cycle.2021Autophagy免费全文
  142. Anatomical sites (Takasaki's segmentation) predicts the recurrence-free survival of hepatocellular carcinoma.2021BMC surgery免费全文
  143. Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity.2021Biochemical and biophysical research communications
  144. HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues.2021Briefings in bioinformatics
  145. Liver Imaging and Data System (LI-RADS) Version 2018 and Other Imaging Features in Intrahepatic Cholangiocarcinoma in Chinese Adults with vs. without Chronic Hepatitis B Viral Infection.2021Canadian journal of gastroenterology & hepatology免费全文
  146. Intratumoral CD45+CD71+ erythroid cells induce immune tolerance and predict tumor recurrence in hepatocellular carcinoma.2021Cancer letters
  147. Circular RNA circ-102,166 acts as a sponge of miR-182 and miR-184 to suppress hepatocellular carcinoma proliferation and invasion.2021Cellular oncology (Dordrecht, Netherlands)免费全文
  148. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.2021Clinical and experimental medicine
  149. Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: A propensity score-matched analysis.2021Clinics and research in hepatology and gastroenterology
  150. Prognostic Significance of Hematopoietic-cell Serglycin for the Survival of Hepatocellular Carcinoma: A Single-center Retrospective Study.2021Combinatorial chemistry & high throughput screening
  151. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria.2021European journal of gastroenterology & hepatology
  152. Diagnostic performance of LI-RADS for MRI and CT detection of HCC: A systematic review and diagnostic meta-analysis.2021European journal of radiology
  153. Preoperative prediction of pathologic grade of HCC on gadobenate dimeglumine-enhanced dynamic MRI.2021European radiology
  154. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.2021European radiology
  155. TMEM2 binds to CSNK2A3 to inhibit HBV infection via activation of the JAK/STAT pathway.2021Experimental cell research
  156. Letter to the Editor: Should Growth Pattern of Hepatocellular Carcinoma Be Constant and Homogenous?2021Hepatology (Baltimore, Md.)
  157. Preoperative identification of microvascular invasion in hepatocellular carcinoma by XGBoost and deep learning.2021Journal of cancer research and clinical oncology免费全文
  158. circNFATC3 sponges miR-548I acts as a ceRNA to protect NFATC3 itself and suppressed hepatocellular carcinoma progression.2021Journal of cellular physiology
  159. Phosphorylation of NF-κBp65 drives inflammation-mediated hepatocellular carcinogenesis and is a novel therapeutic target.2021Journal of experimental & clinical cancer research : CR免费全文
  160. Accuracies of Chemical Shift In/Opposed Phase and Chemical Shift Encoded Magnetic Resonance Imaging to Detect Intratumoral Fat in Hepatocellular Carcinoma.2021Journal of magnetic resonance imaging : JMRI
  161. Expression and prognostic roles of PRDXs gene family in hepatocellular carcinoma.2021Journal of translational medicine免费全文
  162. Utility of Fusion Imaging for Percutaneous Thermal Ablation of Hepatocellular Carcinoma in the Caudate Lobe.2021Journal of vascular and interventional radiology : JVIR
  163. Dynamic Contrast-Enhanced Ultrasound Radiomics for Hepatocellular Carcinoma Recurrence Prediction After Thermal Ablation.2021Molecular imaging and biology
  164. GTSE1 promotes SNAIL1 degradation by facilitating its nuclear export in hepatocellular carcin oma cells.2021Molecular medicine reports免费全文
  165. Prognostic Value of Serum Apolipoprotein B to Apolipoprotein A-I Ratio in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization: A Propensity Score-Matched Analysis.2021Oncology research and treatment免费全文
  166. Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma.2021Radiographics : a review publication of the Radiological Society of North America, Inc
  167. APS (Age, Platelets, 2D Shear-Wave Elastography) Score Predicts Hepatocellular Carcinoma in Chronic Hepatitis B.2021Radiology
  168. Neutrophil-to-Apolipoprotein A1 Ratio Predicted Overall Survival in Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.2021The oncologist免费全文
  169. Intra-Procedural CT/MR-Ultrasound Fusion Imaging Helps to Improve Outcomes of Thermal Ablation for Hepatocellular Carcinoma: Results in 502 Nodules.2021Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  170. Clinical and Contrast-enhanced Ultrasound Characteristics of Epithelioid and Classic Hepatic Angiomyolipoma: Comparison With Alpha-fetoprotein-negative Hepatocellular Carcinoma.2021Ultrasound in medicine & biology
  171. Identification and validation of three core genes in p53 signaling pathway in hepatitis B virus-related hepatocellular carcinoma.2021World journal of surgical oncology免费全文
中文论文(未计入)2
  1. [Multi-omics combined test performance effectiveness on opportunistic screening of high-risk liver cancer population].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Effect of HBV DNA load on the safety and prognosis of systematic therapy in advanced hepatocellular carcinoma].2024Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)27
  1. TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT正在招募NCT05984511牵头方不分期2023-08 启动
  2. Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC正在招募NCT05484908牵头方不分期2022-08 启动
  3. TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC状态不明NCT05250843牵头方II/III期2022-05 启动
  4. Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation状态不明NCT04564313牵头方I期2020-09 启动
  5. Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control Trial状态不明NCT02817685牵头方2016-05 启动
  6. Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation状态不明NCT02399735牵头方I期2014-10 启动
  7. Radiomics for Diagnosing Liver Diseases and Evaluating Progression状态不明NCT03221049牵头方2011-01 启动
  8. Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC即将招募NCT06900478牵头方(推断)II期2025-03 启动
  9. Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies状态不明NCT05803928牵头方(推断)I期2024-01 启动
  10. Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy状态不明NCT05620004牵头方(推断)I/II期2021-11 启动
  11. A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)已完成NCT03086564牵头方(推断)I/II期2017-05 启动
  12. A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC正在招募NCT07589244研究中心II/III期2026-05 启动
  13. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma即将招募NCT06779461研究中心III期2025-01 启动
  14. Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.正在招募NCT06746701研究中心2023-05 启动
  15. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  16. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  17. A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization已完成NCT06503250研究中心2024-07 启动
  18. A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).已终止NCT05975645研究中心I期2023-08 启动
  19. A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification状态不明NCT05313282研究中心III期2022-06 启动
  20. A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)状态不明NCT05214339研究中心II期2022-03 启动
  21. Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients状态不明NCT05343832研究中心2021-11 启动
  22. Performance Evaluation (Sensitivity/Specificity) of HelioLiver Test for Detection of HCC已完成NCT05059665研究中心2020-04 启动
  23. Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection已撤回NCT04044651研究中心II/III期2019-10 启动
  24. A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation已撤回NCT03634683研究中心I/II期2018-08 启动
  25. A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation状态不明NCT02719782研究中心I期2015-07 启动
  26. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC状态不明NCT03313596研究中心III期2013-03 启动
  27. Urea Cream Treatment Sorafenib-Associated HSFR in HCC已完成NCT01934829研究中心II期2009-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.1%。

牵头论文
15
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 1120232024: 2220242025: 332025

广州有 15 家医院列在胃癌下全国有 211 家医院列在胃癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。

这些数字背后的记录
研究主题影像与人工智能营养与康复腹膜转移与晚期
论文中的科室病理/检验科消化/肝病科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文15
  1. An emerging entity of gastric adenocarcinoma: clinicopathological features and differential diagnosis of gastric adenocarcinoma of fundic-gland type in 25 retrospective cases.2026Virchows Archiv : an international journal of pathology
  2. Tepotinib interaction triggers a slight effect on the overall stability of hemoglobin protein, reinforcing the potential suitability as a drug candidate against gastric cancer.2025International journal of biological macromolecules
  3. PUF60 Promotes Chemoresistance Through Drug Efflux and Reducing Apoptosis in Gastric Cancer.2025International journal of medical sciences免费全文
  4. Combined Oxaliplatin with 5-Fluorouracil for Effective Chemotherapy Against Gastric Cancer in Animal Model.2025International journal of nanomedicine免费全文
  5. Mitochondrial dysfunction induced by HIF-1α under hypoxia contributes to the development of gastric mucosal lesions.2024Clinical and translational medicine免费全文
  6. Prognostic value of a modified pathological staging system for gastric cancer based on the number of retrieved lymph nodes and metastatic lymph node ratio.2024PeerJ免费全文
  7. CD45- erythroid progenitor cells promote lymph node metastasis in gastric cancer by inducing a hybrid epithelial/mesenchymal state in lymphatic endothelial cells.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  8. Hypoxia-induced ebv-circLMP2A promotes angiogenesis in EBV-associated gastric carcinoma through the KHSRP/VHL/HIF1α/VEGFA pathway.2022Cancer letters
  9. ebv-circRPMS1 promotes the progression of EBV-associated gastric carcinoma via Sam68-dependent activation of METTL3.2022Cancer letters
  10. EBV-Induced CXCL8 Upregulation Promotes Vasculogenic Mimicry in Gastric Carcinoma via NF-κB Signaling.2022Frontiers in cellular and infection microbiology免费全文
  11. Gastroesophageal reflux is associated with an increased risk of gastric cardiac polyps: a case-control study of 140 cases.2021Annals of palliative medicine
  12. Prognostic Value of Tumor-Infiltrating Lymphocytes and Tertiary Lymphoid Structures in Epstein-Barr Virus-Associated and -Negative Gastric Carcinoma.2021Frontiers in immunology免费全文
  13. Prognostic value of LRRC4C in Colon and Gastric Cancers correlates with Tumour Microenvironment Immunity.2021International journal of biological sciences免费全文
  14. A Smart Multifunctional Nanoparticle for Enhanced Near-Infrared Image-Guided Photothermal Therapy Against Gastric Cancer.2021International journal of nanomedicine免费全文
  15. Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute pancreatitis: A case report.2021World journal of gastroenterology免费全文
中文论文(未计入)1
  1. [Completely laparoscopic radical treatment of distal gastric cancer through natural orifice specimen extraction surgery: past, present, and future].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer状态不明NCT05545436牵头方II期2022-09 启动
  2. Single-center Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer状态不明NCT02219854牵头方不分期2014-07 启动
  3. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis状态不明NCT03023436研究中心III期2016-01 启动
  4. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)状态不明NCT01609309研究中心III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 8 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.09%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

广州有 30 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 12 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Endoscopy-Assisted Laparoscopic Resections for Gastric Gastrointestinal Stromal Tumors: A Retrospective Study.2017Journal of laparoendoscopic & advanced surgical techniques. Part A

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

广州有 22 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025

广州有 14 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

广州有 5 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 18 家医院列在β 地中海贫血下全国有 133 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
早期论文(2016–2020 年)3
  1. Prediction of K562 Cells Functional Inhibitors Based on Machine Learning Approaches.2019Current pharmaceutical design
  2. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.2018Stem cells translational medicine
  3. Up-regulation of NKG2A inhibitory receptor on circulating NK cells contributes to transfusion-induced immunodepression in patients with β-thalassemia major.2016Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

广州有 3 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 39 篇,占 8.0%。

牵头论文
39
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 121220212022: 7720222023: 8820232024: 8820242025: 442025

广州有 9 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
    分期
    不分期
    开始
    2025-04
    登记号
    NCT06763848

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学附属第三医院广州

  2. 正在招募
    Cohort Study on Neuroimmune Diseases in the Reproductive Age
    分期
    未注明
    开始
    2024-04
    登记号
    NCT07653984

    年龄 20 岁 至 55 岁;仅女性(登记的条件)

    牵头:中山大学附属第三医院广州

  3. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断急性发作治疗影像
论文中的科室神经内科病理/检验科
牵头的论文39
  1. Impact of Treatment Delay and Prognostic Factors in Acute Myelitis of Neuromyelitis Optica Spectrum Disease.2025Brain and behavior免费全文
  2. Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4-IgG-positive neuromyelitis optica spectrum disorder during acute attacks.2025British journal of clinical pharmacology
  3. Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.2025Journal of neurology
  4. Risk of hepatitis B and tuberculosis reactivation in patients with neuromyelitis optica spectrum disorder undergoing B cell depletion therapy.2025Multiple sclerosis and related disorders
  5. A comparative study of hypothalamic involvement in patients with myelin oligodendrocyte glycoprotein antibody-associated disease, neuromyelitis optica spectrum disorder, and multiple sclerosis.2024European journal of neurology免费全文
  6. Hypothalamic Dysfunction, Bilateral Vertical Gaze Palsy, and Psychiatric Symptoms in Neuromyelitis Optica Spectrum Disorders: A Case Report.2024Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  7. Probiotics-regulated lithocholic acid suppressed B-cell differentiation in neuromyelitis optica spectrum disorder.2024Journal of neuroimmunology
  8. Combination of serum markers with optical coherence tomography angiography for evaluating neuromyelitis optica spectrum disorders and multiple sclerosis.2024Multiple sclerosis and related disorders
  9. Characteristics of recurrence risk perception and coping strategies in patients with neuromyelitis optica spectrum disorder: A qualitative study.2024Multiple sclerosis and related disorders
  10. Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease.2024Multiple sclerosis and related disorders
  11. Lycium barbarum glycopeptide ameliorates motor and visual deficits in autoimmune inflammatory diseases.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  12. Astrocyte-secreted C3 signaling impairs neuronal development and cognition in autoimmune diseases.2024Progress in neurobiology
  13. Integrative analysis of purine metabolites and gut microbiota in patients with neuromyelitis optica spectrum disorders after mycophenolate mofetil treatment.2023BMC neurology免费全文
  14. Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks.2023European journal of neurology
  15. Remyelination in neuromyelitis optica spectrum disorder is promoted by edaravone through mTORC1 signaling activation.2023Glia
  16. Rapid Immunodot AQP4 Assay for Neuromyelitis Optica Spectrum Disorder.2023JAMA neurology免费全文
  17. Predictors for acute respiratory failure in AQP4-IgG-positive neuromyelitis optica spectrum disorders patients with medullary lesions.2023Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  18. Decreased kynurenine in cerebrospinal fluid and potential role in neuromyelitis optica spectrum disorder.2023Journal of neurochemistry
  19. A novel rare variant of CNPY3 from familial NMOSD impairs the TLR-mediated immune response.2023Journal of neuroimmunology
  20. Inhibition of complement C3 signaling ameliorates locomotor and visual dysfunction in autoimmune inflammatory diseases.2023Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  21. Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation.2022European journal of neurology
  22. Gut Microbiome and Bile Acid Metabolism Induced the Activation of CXCR5+ CD4+ T Follicular Helper Cells to Participate in Neuromyelitis Optica Spectrum Disorder Recurrence.2022Frontiers in immunology免费全文
  23. Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms.2022Journal of neuroimmunology
  24. Cerebrospinal fluid cystatin C levels in patients with anti-NMDAR encephalitis and other neurological diseases.2022Journal of neuroimmunology
  25. Clinical and genetic analysis of familial neuromyelitis optica spectrum disorder in Chinese: associated with ubiquitin-specific peptidase USP18 gene variants.2022Journal of neurology, neurosurgery, and psychiatry
  26. Social participation and quality of life among patients with neuromyelitis optica spectrum disorders: The mediating effects of depression.2022Multiple sclerosis and related disorders
  27. Steroid-induced central serous chorioretinopathy in neuromyelitis optica spectrum disorders: a case report.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  28. Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study.2021BMC neurology免费全文
  29. Optical coherence tomography angiography helps distinguish multiple sclerosis from AQP4-IgG-seropositive neuromyelitis optica spectrum disorder.2021Brain and behavior免费全文
  30. Serum antinuclear antibodies associate with worse prognosis in AQP4-positive neuromyelitis optica spectrum disorder.2021Brain and behavior免费全文
  31. Whole-exome sequencing reveals the major genetic factors contributing to neuromyelitis optica spectrum disorder in Chinese patients with aquaporin 4-IgG seropositivity.2021European journal of neurology
  32. Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study.2021Frontiers in immunology免费全文
  33. Hypothalamic lesions in neuromyelitis optica spectrum disorders: exploring a scoring system based on magnetic resonance imaging.2021Japanese journal of radiology
  34. High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders.2021Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  35. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.2021Journal of neurochemistry
  36. Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone.2021Journal of neuroimmunology
  37. The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China.2021Journal of neuroimmunology
  38. Clinical Characteristics of Chinese Male Patients with Aquaporin-4 Antibody-Positive Late-Onset Neuromyelitis Optica Spectrum Disorder.2021Neuroimmunomodulation
  39. Male patients with neuromyelitis optica spectrum disorders: different clinical characteristics and worse steroid treatment response.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder正在招募NCT06763848牵头方不分期2025-04 启动
  2. Cohort Study on Neuroimmune Diseases in the Reproductive Age正在招募NCT07653984牵头方2024-04 启动
  3. Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders状态不明NCT04101058牵头方2019-01 启动
  4. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动
  5. An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit已完成NCT04388072研究中心2020-05 启动
PubMed 以外找到的论文(未计入)4
  1. The Risk of Hepatitis B and Tuberculosis Reactivation in Patients with Neuromyelitis Optica Spectrum Disorder Treated with B-Cell Depletion Therapy (P7-8.010)2025Neurology论文
  2. New Insights Into the Metabolic Capacity of Gut Microbiota in Coordinating the Efficacy of Mycophenolate Mofetil in Neuromyelitis Optica Spectrum Disorders2022Research Square预印本
  3. Research progress of neuroregeneration in neuromyelitis optica spectrum disorders2022DOAJ (DOAJ: Directory of Open Access Journals)论文
  4. Research progress of single⁃cell omics in central nervous system immune diseases2022DOAJ (DOAJ: Directory of Open Access Journals)论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年没有牵头重症肌无力的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头

广州有 7 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Cohort Study on Neuroimmune Diseases in the Reproductive Age
    分期
    未注明
    开始
    2024-04
    登记号
    NCT07653984

    年龄 20 岁 至 55 岁;仅女性(登记的条件)

    牵头:中山大学附属第三医院广州

  2. 正在招募
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    分期
    I期
    开始
    2025-09
    登记号
    NCT07215650

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、天津、太原、广州、成都、福州、贵阳、郑州、长春

  3. 正在招募
    Myasthenia Gravis Registry in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06241521

    年龄未注明(登记的条件)

    牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 2220242025: 002025

广州有 3 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题血管重建手术影像与脑血流中风与出血
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年没有牵头肝豆状核变性的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 5 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝豆状核变性开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver Failure状态不明NCT03589820牵头方不分期2018-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 22 篇,占 8.3%。

牵头论文
22
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 4420222023: 3320232024: 0020242025: 992025

广州有 12 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科病理/检验科
牵头的论文22
  1. Glymphatic dysfunction as an indicator of disease burden and a potential biomarker in anti-NMDAR encephalitis.2026Psychiatry and clinical neurosciences
  2. Overlapping autoimmune encephalitis with tripartite autoantibody positivity (NMDAR, GFAP, mGluR5) associated with papillary thyroid carcinoma: a case report.2025BMC neurology
  3. Elevated Prolactin Levels Are Associated With Increased Severity and Psychiatric Symptoms in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.2025Brain and behavior
  4. IRF7 in peripheral monocytes drives BBB disruption in anti-NMDAR encephalitis.2025Brain, behavior, and immunity
  5. Safety and Efficacy of a Neonatal Fc Receptor Antagonist in Patients With Anti-NMDAR Encephalitis.2025CNS neuroscience & therapeutics
  6. Serum neuron-specific enolase can predict the severity and outcome of anti-N-methyl-D-aspartate receptor encephalitis.2025Clinica chimica acta; international journal of clinical chemistry
  7. Immunoregulatory programs in anti-N-methyl-D-aspartate receptor encephalitis identified by single-cell multi-omics analysis.2025Clinical and translational medicine
  8. Machine Learning and Shapley Additive Explanations Value Integration for Predicting the Prognostic of Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Model Development and Evaluation Study.2025JMIR medical informatics
  9. Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks.2025Life sciences
  10. Alterations of long-range association fibers in patients with anti-N-methyl-D-aspartate receptor encephalitis.2025NeuroImage. Clinical
  11. Serum neurofilament light chain is associated with disturbed limbic-based functional connectivity in patients with anti-NMDAR encephalitis.2023Journal of neurochemistry
  12. Cerebrospinal fluid uric acid levels associated with disease severity in patients with anti-N-methyl-d-aspartate receptor encephalitis.2023Journal of neuroimmunology
  13. Transfer of patient's peripheral blood mononuclear cells (PBMCs) disrupts blood-brain barrier and induces anti-NMDAR encephalitis: a study of novel humanized PBMC mouse model.2023Journal of neuroinflammation
  14. Simple and effective serum biomarkers potential for predicting status epilepticus in anti-N-methyl-D-aspartate receptor encephalitis.2022BMC neurology
  15. Cerebrospinal fluid cystatin C levels in patients with anti-NMDAR encephalitis and other neurological diseases.2022Journal of neuroimmunology
  16. Dysregulated CD40 and CD40 ligand expression in anti-N-methyl-d-aspartate receptor encephalitis.2022Journal of neuroimmunology
  17. Serum NfL associated with anti-NMDA receptor encephalitis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  18. Anti-N-Methyl-D-Aspartate Receptor Encephalitis Associated with Ovarian Teratoma in South China-Clinical Features, Treatment, Immunopathology, and Surgical Outcomes of 21 Cases.2021Disease markers
  19. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is associated with IRF7, BANK1 and TBX21 polymorphisms in two populations.2021European journal of neurology
  20. Successful treatment with immunoadsorption therapy in four patients with severe and refractory anti-N-methyl-D-aspartate receptor encephalitis.2021Journal of clinical apheresis
  21. Association of serum Gasdermin D with anti-N-methyl-D-aspartate receptor encephalitis.2021Journal of neurochemistry
  22. Protein A immunoadsorption for the treatment of refractory anti-N-methyl-d-aspartate receptor encephalitis: A single-center prospective study.2021Journal of the neurological sciences
早期论文(2016–2020 年)9
  1. HLA class II allele DRB1*16:02 is associated with anti-NMDAR encephalitis.2019Journal of neurology, neurosurgery, and psychiatry
  2. Serum cystatin C and anti-N-methyl-D-aspartate receptor encephalitis.2018Acta neurologica Scandinavica
  3. Serum complement levels in anti-N-methyl-d-aspartate receptor encephalitis.2018European journal of neurology
  4. Anti-thyroid antibodies and thyroid function in anti-N-methyl-d-aspartate receptor encephalitis.2018Neurochemistry international
  5. Serum Bilirubin and Albumin in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.2018Neuroimmunomodulation
  6. Serum uric acid and anti-N-methyl-d-aspartate receptor encephalitis.2017Neurochemistry international
  7. Low serum vitamin D levels and anti-N-methyl-d-aspartate receptor encephalitis: A case-control study.2017Neurochemistry international
  8. [Ovarian tumor associated with anti-N-methyl-D-aspartate receptor encephalitis: a report of 15 cases].2017Zhonghua yi xue za zhi
  9. Brainstem and vestibulocochlear nerve involvement in relapsing-remitting anti-NMDAR encephalitis.2016Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies即将招募NCT07858175牵头方2026-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

广州有 6 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 20 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

广州有 13 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

广州有 7 家医院列在白塞病下全国有 139 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. The value of endografts in the surgical management of arterial lesions secondary to Behçet disease.2017Journal of vascular surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

广州有 5 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

广州有 16 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Correlation of Microbiome and Metabonomics With IgA Nephropathy
    分期
    未注明
    开始
    2020-05
    登记号
    NCT05190848

    年龄 16 岁 至 65 岁(登记的条件)

    牵头:广东省人民医院;另有 4 家列出的医院为研究中心广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

尼曼-匹克病 C 型

Niemann–Pick disease type C

2021–2025 年没有牵头尼曼-匹克病 C 型的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 1 家医院列在尼曼-匹克病 C 型下全国有 15 家医院列在尼曼-匹克病 C 型下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尼曼-匹克病 C 型开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. In Vivo Assessment of Neurodegeneration in Type C Niemann-Pick Disease by IDEAL-IQ.2018Korean journal of radiology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

广州有 9 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科消化/肝病科
牵头的论文2
  1. The effects of lifestyle factors on primary biliary cholangitis ascertained by two-sample Mendelian randomization.2026The American journal of the medical sciences
  2. Comprehensive analysis of immune signatures in primary biliary cholangitis and autoimmune hepatitis.2024Journal of leukocyte biology
早期论文(2016–2020 年)3
  1. Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis.2020BioMed research international
  2. Dysregulation of Circulating FGF19 and Bile Acids in Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome.2020BioMed research international
  3. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis.2017PloS one
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Probiotics in PBC Patients of Poor Response to UDCA状态不明NCT03521297牵头方(推断)II期2020-01 启动
  2. Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response已完成NCT03590886牵头方(推断)2018-08 启动
  3. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动
  4. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)进行中,不再招募NCT05896124研究中心II期2023-08 启动
  5. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 8 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年没有牵头遗传性血管性水肿的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 3 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Diagnosis and treatment procedures and health management for patients with hereditary angioedema].2023Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

中山大学附属第三医院

Third Affiliated Hospital of Sun Yat-sen University

广州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Third Affiliated Hospital of Sun Yat-Sen University; Third Affiliated Hospital of Sun Yat‑sen University; Third Affiliated Hospital of Sun Yat-sen University (SYSU); Third Affiliated Hospital of Zhongshan Medical University

提出更正下载数据